6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

Subjects:

Wear morphology: (a) UT, (b) SP1, (c) SP2, and (d) SP3. by Huashen Guan (20454677)

Subjects:

Residual stress of various samples: (a) surface residual stress and (b) residual stress in the depth direction. by Huashen Guan (20454677)

Subjects:

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

Subjects:

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

Subjects:

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects:

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

Subjects:

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

Subjects:

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects:

DIO Mice Liver Staining. by Xueqin lu (22250795)

Subjects:

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects: